Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US
Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US as Millions Fewer People Line Up
(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV,
Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated
On Monday, Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist investor Starboard Value has invested approximately $1 billion in Pfizer as the pharmaceutical giant grapples with a downturn in demand for COVID-19 vaccines and treatments.
U.K. court rules in Pfizer's favor in GSK RSV vaccine dispute: report
Pfizer (PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (GSK) patents for its RSV vaccine. Read more here.
21h
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...
8h
GSK shares jump on $2.2 billion Zantac settlement
GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits ...
FiercePharma
3h
Pfizer targets broad Talzenna approval in prostate cancer as trial meets patient survival goal
In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...
6h
on MSN
UK firm GSK to pay $2.2bn over Zantac cancer claims
UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...
16h
Zantac maker GSK agrees to pay $2.3 bn in US settlements
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...
FiercePharma
22h
GSK will pony up $2.2B to resolve 80K Zantac cases
The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.
1d
What's Happening With Pfizer Stock?
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
kffhealthnews
1d
GSK’s Widely Used RSV Shot Retains 43% Potency In Third Year, Data Show
Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...
5h
on MSN
GSK Shares Climb on $2.2 Billion Zantac Lawsuit Settlement
GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands ...
STAT
3h
Pharmalittle: We’re reading about Pfizer struggles with Starboard, Lilly going after compounders, and more
Two former Pfizer executives said they will not be involved with activist investor Starboard Value, which reportedly wants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Zantac
GlaxoSmithKline
Ranitidine
Feedback